# Allogenic CD19-targeting CAR-γδT Cell Therapy in R/R NHL

> **NCT05554939** · PHASE1,PHASE2 · RECRUITING · sponsor: **Chinese PLA General Hospital** · enrollment: 30 (estimated)

## Conditions studied

- Non Hodgkin's Lymphoma

## Interventions

- **BIOLOGICAL:** Allogenic CD19 CAR-γδT cell
- **DRUG:** Fludarabine
- **DRUG:** Cyclophosphamide

## Key facts

- **NCT ID:** NCT05554939
- **Lead sponsor:** Chinese PLA General Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2022-12-11
- **Primary completion:** 2026-12-31
- **Final completion:** 2027-12-31
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2025-08-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05554939

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05554939, "Allogenic CD19-targeting CAR-γδT Cell Therapy in R/R NHL". Retrieved via AI Analytics 2026-07-27 from https://api.ai-analytics.org/clinical/NCT05554939. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*